The FDA’s enactment of policies regarding clinical trial diversity signals a watershed moment in the conduct of clinical research. Once upon a time, clinical trials completely excluded minorities, women, older adults, and lower socioeconomic groups for decades. Now sponsors and researchers will have to implement Diversity Action Plans, inclusive design, and community engagement. Furthermore, sponsors will be expected to ensure equity, cultural competence, and diverse leadership are prioritized. Using new innovations in decentralized trials, m-health, and global harmonization will increase trust, data quality, and outcomes. This is not merely compliance—it is a radical move toward scientific integrity, social justice, and global health equity.